Last updated: February 23, 2026
Case Overview
Actelion Pharmaceuticals Ltd. filed a patent infringement lawsuit against Mylan Pharmaceuticals Inc. (Case No. 1:20-cv-00110-IMK) in the U.S. District Court for the Southern District of West Virginia. The case centers on Mylan’s attempts to market generic versions of Opsumit (macitentan), a drug approved for pulmonary arterial hypertension, allegedly infringing on Actelion's patents.
Patents in Dispute
- U.S. Patent Nos. 8,598,219 and 9,519,771: These cover the composition of matter and methods of using macitentan.
- The patents are set to expire between 2030 and 2034, with Actelion asserting that Mylan's generic application infringes these claims.
Key Litigation Points
Alleged Patent Infringement
Actelion claims Mylan’s ANDA (Abbreviated New Drug Application) filing infringes their patents by seeking approval to produce generic macitentan before patent expiry. Actelion argues that Mylan’s product at issue would violate the patents' scope.
Paragraph IV Certification
Mylan’s ANDA submission included a Paragraph IV certification, asserting that the patents are invalid or not infringed. This typically triggers a patent infringement suit under the Hatch-Waxman Act and signals Mylan’s intent to challenge the patents.
Court Proceedings
- Infringement Claims: Actelion’s complaint alleges that Mylan’s generic infringing product would infringe on the asserted patents.
- Declaratory Judgment: Actelion seeks a court declaration that their patents are valid and will be infringed by Mylan’s product.
- Preliminary Injunction: Actelion has sought to prevent Mylan from launching until patent validity is resolved.
Defense and Countermeasures
Mylan contends the patents are invalid due to obviousness, lack of novelty, or inadequate written description. Mylan also argues their product does not infringe because it differs in formulation or manufacturing process.
Settlement and Patent Term Extensions
Actelion may seek extensions or adjustments, while Mylan prepares for potential patent litigation defenses or settlement negotiations. The case remains ongoing, with a scheduled trial date.
Strategic and Industry Implications
- Market Impact: A ruling in favor of Actelion could delay Mylan’s entry, maintaining exclusivity until patent expiry or license settlement.
- Patent Validity Attacks: Mylan’s invalidity defenses, if successful, could open the market to generic competition sooner.
- Legal Trends: This case reflects the ongoing pattern of litigation surrounding biologic and specialty drug patent rights, highlighting the importance of patent strength and freedom-to-operate assessments.
Timetable and Next Steps
- Initial Case Management Conference: Completed, with court establishing procedural schedules.
- Discovery Phase: Expected to involve technical patent analyses, expert testimony, and potentially market analysis.
- Trial Expectation: Likely in 2024, depending on case progression.
Conclusion
This litigation exemplifies the ongoing confrontations between originator pharmaceutical companies and generic challengers over patent rights, particularly involving complex biologics like macitentan. The outcome will influence Mylan’s timeline for market entry and could shape patent enforcement strategies for biologics.
Key Takeaways
- Actelion’s patents cover key aspects of macitentan and are under challenge through Mylan’s ANDA and Paragraph IV certification.
- The case hinges on claims of patent validity and infringement, with potential delays for Mylan if Actelion succeeds.
- The dispute underscores the importance of patent strength in biologic markets and the use of Hatch-Waxman procedures to challenge exclusivity.
- A decision is expected in 2024, with significant market and legal implications for both parties.
FAQs
Q1: What is the significance of a Paragraph IV certification?
A: It indicates the generic applicant challenges patent validity or infringement, prompting a patent infringement lawsuit.
Q2: How long could the litigation delay the launch of Mylan’s generic macitentan?
A: Potentially until the court rules on patent validity, likely delaying possible market entry until 2024 or later.
Q3: What are common defenses against patent infringement claims in this context?
A: Challenges include patent invalidity due to obviousness, lack of novelty, or non-infringement based on product differences.
Q4: What is the role of patent extensions in this case?
A: Actelion may seek extensions or supplementary protections, but these are limited by statutory rules and patent age at filing.
Q5: How does this case compare with other biologic patent litigations?
A: It reflects typical disputes over patent scope, validity, and biosimilar entry timing, common across the biologic pharmaceutical sector.
References
- U.S. District Court, Southern District of West Virginia. (2020). Actelion Pharmaceuticals Ltd. v. Mylan Pharmaceuticals Inc. Case No. 1:20-cv-00110-IMK.
- Hatch-Waxman Act, 21 U.S.C. § 355 (1984).
